• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

J Clin Lipidol . Serum 25-hydroxycholesterol levels are increased in patients with coronavirus disease 2019

tetano

Editor, Senior Moderator
J Clin Lipidol


. 2022 Nov 6;S1933-2874(22)00296-3.
doi: 10.1016/j.jacl.2022.10.012. Online ahead of print.
Serum 25-hydroxycholesterol levels are increased in patients with coronavirus disease 2019


Takumi Asano[SUP] 1 [/SUP], Tetsuji Wakabayashi[SUP] 1 [/SUP], Yasuyuki Kondo[SUP] 1 [/SUP], Kenta Okada[SUP] 1 [/SUP], Daisuke Yamamuro[SUP] 1 [/SUP], Yukiko Koga[SUP] 1 [/SUP], Kiyonori Oka[SUP] 1 [/SUP], Momoe Sakurai[SUP] 1 [/SUP], Nagisa Sawayama[SUP] 1 [/SUP], Manabu Takahashi[SUP] 1 [/SUP], Hiroaki Okazaki[SUP] 1 [/SUP], Ken Ebihara[SUP] 1 [/SUP], Kensuke Minami[SUP] 2 [/SUP], Yuji Morisawa[SUP] 2 [/SUP], Shuji Hatakeyama[SUP] 3 [/SUP], Masami Matsumura[SUP] 3 [/SUP], Shun Ishibashi[SUP] 4 [/SUP]



Affiliations

Abstract

Background: 25-hydroxycholesterol (25HC), produced by cholesterol 25-hydroxylase (CH25H) in macrophages, has been reported to inhibit the replication of viral pathogens such as severe acute respiratory syndrome coronavirus-2. Also, CH25H expression in macrophages is robustly induced by interferons (IFNs).
Objective: To better understand the serum level increase of 25HC in coronavirus disease 2019 (COVID-19) and how it relates to the clinical picture.
Methods: We measured the serum levels of 25HC and five other oxysterols in 17 hospitalized COVID-19 patients.
Results: On admission, 25HC and 27-hydroxycholesterol (27HC) serum levels were elevated; however, 7-ketocholesterol (7KC) levels were lower in patients with COVID-19 than in the healthy controls. There was no significant correlation between 25HC serum levels and disease severity markers, such as interferon-gamma (IFN-γ) and interleukin 6. Dexamethasone effectively suppressed cholesterol 25-hydroxylase (CH25H) mRNA expression in RAW 264.7 cells, a murine leukemia macrophage cell line, with or without lipopolysaccharide or IFNs; therefore, it might mitigate the increasing effects of COVID-19 on the serum levels of 25HC.
Conclusions: Our results highlighted that 25HC could be used as a unique biomarker in severe COVID-19 and a potential therapeutic candidate for detecting the severity of COVID-19 and other infectious diseases.

Keywords: 25-Hydroxycholesterol; COVID-19; Cholesterol 25-hydroxylase; Oxysterol; Serum biomarker.
 
Back
Top Bottom